These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22971479)

  • 1. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma.
    Zhang G; Liang Y; Huang Y; Chen Y; Zhou R
    J Int Med Res; 2012; 40(4):1275-83. PubMed ID: 22971479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
    Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
    PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.
    Qiao M; Hu G
    Tumour Biol; 2015 Sep; 36(10):7493-9. PubMed ID: 25910706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
    Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
    Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
    Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.
    Yin M; Lou C; Zhang W; Meng F; Zhang H; Ning X; Zhou R; Dong X; Lou G
    Int J Gynecol Cancer; 2012 Jan; 22(1):54-62. PubMed ID: 22193644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
    Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
    Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
    Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
    PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
    Meng F; Tan S; Liu T; Song H; Lou G
    Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
    Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
    Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
    Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
    PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.
    Kang Y; Yin M; Jiang W; Zhang H; Xia B; Xue Y; Huang Y
    Am J Surg; 2012 Nov; 204(5):677-83. PubMed ID: 22578410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
    Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
    Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
    Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
    J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma.
    Zhou L; He XD; Chen J; Cui QC; Qu Q; Rui JA; Zhao YP
    Eur J Cancer; 2007 Mar; 43(4):809-15. PubMed ID: 17276673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis.
    Meng F; Li H; Zhou R; Luo C; Hu Y; Lou G
    Biomarkers; 2013 Mar; 18(2):136-43. PubMed ID: 23312008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
    Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
    J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of lysosome-associated protein transmembrane-4β gene overexpression with the malignant phenotypes of hepatocellular carcinoma.
    Su H; Xu T; Huang X; Zang S; Wang B; Huang Y; Liu J; Huang A
    Pathol Res Pract; 2017 Dec; 213(12):1536-1541. PubMed ID: 29108920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.